Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2026-01-10 @ 2:58 PM
Study NCT ID:
NCT04002102
Status:
COMPLETED
Last Update Posted:
2022-02-01
First Post:
2019-06-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Open-Label Placebos to Treat Fatigue in Multiple Sclerosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009103', 'term': 'Multiple Sclerosis'}, {'id': 'D005221', 'term': 'Fatigue'}], 'ancestors': [{'id': 'D020278', 'term': 'Demyelinating Autoimmune Diseases, CNS'}, {'id': 'D020274', 'term': 'Autoimmune Diseases of the Nervous System'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D003711', 'term': 'Demyelinating Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D005947', 'term': 'Glucose'}, {'id': 'D059039', 'term': 'Standard of Care'}, {'id': 'D004522', 'term': 'Educational Status'}], 'ancestors': [{'id': 'D006601', 'term': 'Hexoses'}, {'id': 'D009005', 'term': 'Monosaccharides'}, {'id': 'D000073893', 'term': 'Sugars'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D019984', 'term': 'Quality Indicators, Health Care'}, {'id': 'D011787', 'term': 'Quality of Health Care'}, {'id': 'D006298', 'term': 'Health Services Administration'}, {'id': 'D017530', 'term': 'Health Care Quality, Access, and Evaluation'}, {'id': 'D012959', 'term': 'Socioeconomic Factors'}, {'id': 'D011154', 'term': 'Population Characteristics'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 48}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-02-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-01', 'completionDateStruct': {'date': '2022-01-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-01-31', 'studyFirstSubmitDate': '2019-06-25', 'studyFirstSubmitQcDate': '2019-06-26', 'lastUpdatePostDateStruct': {'date': '2022-02-01', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-06-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-01-19', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Change from baseline general self efficacy for managing chronic conditions at 21 days using the PROMIS instrument', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later, the participant will spend 15 minutes each assessment completing this scale.', 'description': 'The scores for this tool are coded separately for each of the 10 questions and range from 1-5 for questions Global01-06, 08r, 09r, and 10r with 1 being the worst possible score and 5 being the best possible score and a range from 0-10 for question Global07r with 0 being the worst possible score and 10 being the best possible score.'}], 'primaryOutcomes': [{'measure': 'Change from baseline fatigue at 21 days using the Fatigue Severity Scale (FSS).', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later, the participant will spend 10 minutes each assessment completing this scale.', 'description': 'This scale is used to measure fatigue and the scale has a range from 9-63 with 9 being the best possible score and 63 being the worst score.'}, {'measure': 'Change from baseline impact of fatigue at 21 days using the Modified Fatigue Impact Scale (MFIS).', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later, the participant will spend 15 minutes each assessment completing this scale.', 'description': 'This scale is used to measure fatigue and the scale has a range from 0 to 84 with 0 being the best possible score and 84 being the worst score.'}, {'measure': 'Change from baseline quality of life at 21 days using the 36-item Short Form survey (SF-36).', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later, the participant will spend 15 minutes each assessment completing this scale.', 'description': 'The scores for this survey range from 0-100 with 0 being the worst possible score and 100 being the best possible score.'}], 'secondaryOutcomes': [{'measure': 'Change from baseline sleepiness at 21 days using the Epworth Sleepiness Scale (ESS).', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later, the participant will spend 15 minutes each assessment completing this scale.', 'description': 'This scale is used to measure sleepiness and the scale has a range from 0-24 with 0 being the best possible score and 24 being the worst.'}, {'measure': 'Change from baseline neurological functioning at 21 days using the Perceived Deficit Questionnaire 5-Item Version (PDQ-5).', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later, the participant will spend 15 minutes each assessment completing this scale.', 'description': 'The scores for this questionnaire range from 5-25 with 5 being the best possible score and 25 being the worst possible score.'}, {'measure': 'Godin Leisure-Time Exercise Questionnaire', 'timeFrame': 'Participants will complete this scale at baseline and 21 days later', 'description': 'A self-explanatory, brief four-item query of usual leisure-time exercise habits'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Placebo', 'Open-Label'], 'conditions': ['Multiple Sclerosis', 'Fatigue']}, 'referencesModule': {'references': [{'pmid': '40611184', 'type': 'DERIVED', 'citation': 'Baidwan NK, Tracy T, Chiu CY, Nawshin T, Hoenemeyer T, Riser E, Motl R, Fontaine K, Mehta T. Open label placebo to treat fatigue in people with multiple sclerosis: feasibility and preliminary effects. Pilot Feasibility Stud. 2025 Jul 3;11(1):93. doi: 10.1186/s40814-025-01674-w.'}]}, 'descriptionModule': {'briefSummary': 'Fatigue is one of the most prevalent and disabling symptoms of multiple sclerosis. Current treatments, including pharmacological, physical therapy, sleep regulation and psychological interventions are of marginal benefit. Pharmacological treatments have inconsistent evidence. Recent studies show that non-deceptive open-label placebos (OLP) have moderate-to-large effects on symptoms, including fatigue, in adults with a variety of medical conditions.\n\nHence, this is a pilot and feasibility study to obtain data on the feasibility and effects of OLP for multiple sclerosis related fatigue and its impact to provide the basis for a competitive NIH application. This pilot study will be the first study to evaluate whether OLP, that garners full consent and engages patients in their wellness, may offer a safe, effective treatment for multiple sclerosis related fatigue.', 'detailedDescription': "The purpose of this pilot study is to evaluate the feasibility of recruiting, enrolling and retaining participants in a study on the acceptability and effects of a non-deceptive (open-label) administration of placebo pills for treating MS related fatigue. Specific Aim 1 will assess the feasibility endpoints including accrual (enroll 44 participants), retention (80% of the sample) and placebo adherence (90%). Specific Aim 2 will evaluate the between-group changes in fatigue, quality of life, cognitive functioning and self-efficacy. Specific Aim 3 will evaluate participant acceptability, satisfaction and experience.\n\nDesign:\n\nThis pilot study is a randomized control trial consisting of three arms: open label placebo arm, expectancy arm, and usual care arm. The clinical coordinator will review medical records, enroll and consent participants based on the following inclusion criteria: diagnosis of MS, 19 years or older, report of moderate to severe fatigue, PDDS score of \\< 7, and stable dose of DMTs for 90 days.\n\nExclusion criteria consists of: major comorbid conditions and use of off label medications or exercise programs in the past 30 days, and if one is confined to a wheelchair.\n\nBaseline and 21 day tele assessments will involve objective measures performed by a physical therapist, Single Digit Modality Test (SDMT) and Five Time Sit to Stand (FTSST) and subjective questionnaires sent to participant's email including Modified Fatigue Impact Scale (MFIS), Functional Systems Score (FSS), Patient Reported Outcomes Measurement Information System (PROMIS), Perceived Deficits Questionnaire, Epworth Sleepiness Scale, and the SF-36 assess of quality of life. Participants will be randomized by the clinical coordinator after baseline testing. The open label placebo and expectancy arm will meet with the care provider who will follow a scripted orientation that mimics a typical patient-provider interaction when prescribing a medication, including the rationale for effectiveness. The provider will emphasize the importance of adherence to the medication for the open label placebo arm and the breathing exercises for the expectancy arm for the next 21 days. A tracking sheet will be provided to both arms to document adherence. The usual care arm will meet with the care provider who will follow a scripted orientation on fatigue and heat management strategies. All participants will receive educational materials on fatigue and heat management. A day 11 check in call will be made to gauge progress and answer questions. After the 21 day tele assessment is performed, the participant will complete subjective questionnaires via email for 28 day and 35 day follow up."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '19 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* A diagnosis of MS\n* Aged 19 years or older\n* report moderate-to-severe fatigue (i.e., ≥4 on the FSS)\n* Patient Determined Disease Steps score of ≥7.\n\nExclusion Criteria:\n\n* Major comorbid conditions that might influence fatigue (e.g. lupus, chronic fatigue syndrome)\n* Patients treated with off label medications or exercise program in the past 30 days.'}, 'identificationModule': {'nctId': 'NCT04002102', 'briefTitle': 'Open-Label Placebos to Treat Fatigue in Multiple Sclerosis', 'organization': {'class': 'OTHER', 'fullName': 'University of Alabama at Birmingham'}, 'officialTitle': 'Open-Label Placebos to Treat Fatigue in Multiple Sclerosis', 'orgStudyIdInfo': {'id': 'IRB-300003575'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'OLP treatment', 'description': 'Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.', 'interventionNames': ['Other: OLP treatment']}, {'type': 'OTHER', 'label': 'Usual care', 'description': 'Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.', 'interventionNames': ['Other: Usual care']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Expectancy Group', 'description': 'Participants receive educational materials and positive expectancy orientation via Zoom or telephone', 'interventionNames': ['Other: Expectancy Group']}], 'interventions': [{'name': 'OLP treatment', 'type': 'OTHER', 'otherNames': ['Open-Label placebo', 'Glucose Tablet'], 'description': 'Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.', 'armGroupLabels': ['OLP treatment']}, {'name': 'Usual care', 'type': 'OTHER', 'otherNames': ['Standard care'], 'description': 'Remain in standard care after randomization and educational materials.', 'armGroupLabels': ['Usual care']}, {'name': 'Expectancy Group', 'type': 'OTHER', 'otherNames': ['Education'], 'description': 'Educational materials and positive expectancy orientation via Zoom or telephone', 'armGroupLabels': ['Expectancy Group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35209', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Tanner Foundation', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'University of Alabama at Birmingham', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}], 'overallOfficials': [{'name': 'Tapan S Mehta, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Alabama at Birmingham'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'], 'timeFrame': 'Will be posted on CT.gov', 'ipdSharing': 'YES', 'description': 'To be determined. Sharing study protocol, statistical analysis plan, and informed consent.', 'accessCriteria': 'To be determined'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Alabama at Birmingham', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Tapan Shirish Mehta', 'investigatorAffiliation': 'University of Alabama at Birmingham'}}}}